Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT
NCT ID: NCT05783934
Last Updated: 2025-05-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
6 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-27
Study Completion Date
2024-01-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial study is to evaluate the presence of relationships between PET and MRI images indicative of chronic inflammatory activity (smoldering plaques), apparent absence of inflammatory activity (silent plaques without microglial rim), or indicative of more recent inflammatory activity, in contrast-enhanced areas or in T2/Flair-positive areas of not distant onset in patients diagnosed with progressive (secondary or primary) stage multiple sclerosis and in patients in relapse and remission.
Laboratory analysis of serum markers will be performed: neuronal and glial cytoskeletal proteins (e.g., Nf-L, pN-FH, GFAP), and the levels of neurotrophic factors (e.g., BDNF, GDNF) and cytokines (e.g., TNFα, IL-6, IL-1β, interferon) will be evaluated.
Laboratory analysis of serum markers will be performed: neuronal and glial cytoskeletal proteins (e.g., Nf-L, pN-FH, GFAP), and the levels of neurotrophic factors (e.g., BDNF, GDNF) and cytokines (e.g., TNFα, IL-6, IL-1β, interferon) will be evaluated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
NCT01767493
Multiple Sclerosis
COMPLETED
PHASE4
Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation
NCT05147532
Multiple Sclerosis
Inflammatory Disease
UNKNOWN
NA
Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)
NCT06280742
Multiple Sclerosis
NOT_YET_RECRUITING
NA
Imaging of Intracerebral Inflammation in MS
NCT02305264
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis, Primary Progressive
COMPLETED
NA
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
NCT05633875
Multiple Sclerosis (MS)
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system with consequent onset of various sensory, motor, sphincter and sometimes cognitive symptoms. It is characterised by the presence of lympho-monocytic inflammatory infiltrates, demyelination, axonal damage, activation of innate immunity, astrogliosis and remyelination. In the last few years, Magnetic Resonance Imaging (MRI) has made enormous progress in the diagnosis and follow-up of patients, highlighting encephalic and spinal lesions, their number and relative lesion burden, location and cortical involvement as well as the presence of blood-brain barrier alterations in the earliest stages of the disease, associated with the activation of acquired immunity with subsequent inflammatory damage.
The demyelination plaques have on their outer edge a thin wall of iron-containing microglial cells that can be detected by high-resolution magnetic susceptibility MRI sequences and techniques. Such plaques, known by neuropathologists as 'smoldering' plaques, are characterised by a concentrically widening periphery causing myelin and neuronal damage while in the centre of the lesion the process of myelin loss becomes complete. Smoldering plaques, more frequent in progressive forms of the disease, are peculiar of MS compared to other demyelinating diseases and are associated with a negative prognostic significance.
Positron Emission Tomography (PET) is a technique that allows to analyze the in vivo metabolism of certain components of the central nervous system, such as neurons and glia, and, in particular cases, to highlight synaptic function and abnormal protein accumulations. In recent years, PET has been used in MS especially for research purposes: it allows to assess the degree of demyelination and remyelination by using amyloid tracers that bind to the white substance, as well as the degree of microglial activation or synaptic impairment applying particular tracer radio isotopes (TPSO ligands or the glycoprotein 2A of synaptic vesicles). The combination of MRI and PET could provide detailed information not only on the degree and extent of the nervous system impairment, but also on the most affected cell populations, on the metabolic activity of the affected encephalic areas and on the degree of success of the damage repair attempts.
The aim of this research project is to study, applying MRI and PET techniques, a population of progressive MS patients (PMS) with a relatively significant impairment and a population of patients with a relapsing-remitting form of the disease (RRMS) with a less significant neurological impairment. The purpose is to study chronically active or 'smoldering' plaques, with magnetic susceptibility MRI techniques and PET techniques with amyloid tracers, chronically inactive plaques and more recent T2/Flair positive plaques, with or without contrast enhancement, in order to verify and quantify their presence and to correlate their number, morphology and location with the degree of disability, the clinical course, the evolution of the disease and the laboratory data, evaluating in each case the extent of demyelination and remyelination process and the degree of activation of innate immunity. The data obtained will be processed and evaluated to identify MRI and PET differences in the various disease courses and to obtain information on the different desease development paths in patients.
Study design Enrolled patients will undergo a brain MRI, a brain PET scan with amyloid tracer and functional assessment scales at the time of recruitment.
All patients will undergo clinical evaluation and various tests:
* EDSS and MS Functional Composite Scale
* Mini-BESTest
* TUG test, MSWS-12, Berg Balance Scale (BBS)
* The nine hole peg test (9-HPT) for right and left upper limb.
* Cognitive functions assessed by Brief International Cognitive Assessment for MS (BICAMS) and MMSE
Laboratory analysis of serum markers will be performed. Specifically, neuronal and glial cytoskeletal proteins (e.g. Nf-L, pN-FH, GFAP) as brain damage indices (axonal and cellular damage), will be considered and quantified.
The levels of specific neurotrophic factors (e.g. BDNF, GDNF) and cytokines (e.g. TNFα, IL-6, IL-1β, interferon) will be determined; there is evidence of their involvement in synaptic plasticity, cognitive and motor functions, and in the neuroinflammatory processes typical of MS.
MRI protocol Examinations will be performed on a 3T MRI scanner using a 32-channel head coil with sequences optimised and harmonised by the IRCCS Neuroscience Network.
The sequences that will be acquired will be:
1. T1-weighted sagittal volumetric image (MP-RAGE, 1 mm resolution) to study the morphology and encephalon volumetry
2. T2-FLAIR weighted sagittal volumetric image (1 mm resolution) for lesion localisation and contouring
3. a sequence of diffusion-weighted images (EPI, 2.5 mm resolution, b=1000 and 2000 s/mm2, 30 directions per shell) for the study of tissue microstructure and for the identification of pathology-relevant white matter bundles by tractography
4. a 3D multi-echo gradient echo sequence for quantitative susceptibility mapping (1 mm resolution, 8 echoes) for the study of local susceptibility
5. an fMRI resting-state sequence (EPI, 3 mm resolution, 200 volumes with a temporal resolution of 2.4 s) for the study of functional resting state networks.
PET protocol
The PET/CT study will be performed using a dual time acquisition protocol:
\- Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.
A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.
Early acquisition will last 30 minutes.
\- Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake.
All PET reconstructions will have the following characteristics:
* 256 x 256 matrix, FOV 30 cm
* 3D-OSEM reconstruction algorithm with TOF and PSF and with standard corrections for decay, attenuation, scatter, dead time
* 8 iterations, 32 subsets, Gaussian filter with FWHM of 5 mm. Raw data will be available for possible different iterations, decided a posteriori, to improve image quality.
Patients do not need to be fasting or suspending current therapies.
MRI and PET evaluations MRI
1. Automated encephalic morpho-volumetric study (Freesurfer), by acquisition of conventional sequences (T2w, FLAIR 3D, T1w-3D), harmonised according to RIN protocol:
1. cortical thickness;
2. global brain atrophy;
3. lesions burden;
4. Normal-Appearing White Matter (NAWM).
2. Detection and study of chronic "smoldering" lesions using the QSM technique, which allows both qualitative and quantitative assessments of the extent of intralesional iron accumulation:
1. Qualitative assessment:
* Identification of Rim+ lesions, defined as "non-enhancing lesions with hyperintense perilesional rim", with iso-ipointense core;
* Calculation of the global volume of Rim+ lesions (in mm3), with subsequent separate measurement of core and Rim.
2. Quantitative assessment
* calculation of the global susceptibility of the Rim+ lesions (expressed in ppb: parts per billion), compared to the CSF reference value;
* calculation of susceptibility of Rim and core, separately.
3. Active lesions evaluation by assessing:
1. Number of lesions showing contrastographic enhancement (qualitative assessment);
2. Type of enhancement (nodular or shell-enhancement). The various parameters will be evaluated by three operators (radiologists with expertise in neuroradiology), with consensus agreement and a double check at 4 months after the first evaluation.
PET A slightly abbreviated protocol will be used with a 30-minute dynamic acquisition immediately after the injection of 18F-Florbetaben followed by a 20-minute delayed acquisition (this performed between 90 and 110 minutes after injection). The tracer binds to NAWM and in minor extent to the actively demyelinating plaques, which will be quantified. In addition, a semi-quantitative objective methodology will be used to obtain data on the degree of demyelination of the different cases examined by comparison of the data of the region of interest under investigation with NAWM uptake and a reference area uptake.
In particular, the semi-quantification foreseen is a SUVr where the uptake ROIs are the lesions pre-segmented by the neuroradiologist on MRI (FLAIR and T1 sequences), while for the reference ROIs several possibilities will be evaluated: the contralateral uptake ROIs (i.e. in the white matter if apparently normal on MRI), the white matter hot-spots in the late acquisition, the white matter average with the exclusion of the uptake ROIs. The dynamic uptake profile from the early acquisition will also be assessed, using different temporal reconstructions.
This semi-quantitative evaluation will be carried out in collaboration with colleagues from Nuclear Medicine and the National Institute of Nuclear Physics in Genoa, who have extensive experience in the field and have recently published semi-quantitative methods for the evaluation of PET investigation in Alzheimer's disease.
Sample size
This is an exploratory study of correlation between clinical, laboratory, MRI and PET findings. Considerations on sample size are omitted in the current study and may be included and perfectionated in future confirmatory studies.
Expected results The main objective of the study will be to verify the presence of correlations between PET and MRI images indicative of chronic inflammatory activity (smoldering plaques), of apparent absence of inflammatory activity (silent plaques without microglial Rim) or indicative of more recent inflammatory activity, in contrast-enhancing areas or in T2/Flair positive areas of not distant onset.
PET data will be correlated with conventional MRI parameters, and with clinical and laboratory data. The finding of significant correlations would support the role of PET as a useful tool for evaluating demyelination and remyelination activity, which may be characteristic of a certain disease phase or even possibly of specific types of individual patients.
Particular attention will be paid to study chronic lesions considering the promising results reported in recent studies showing the possibility to distinguish silent lesions from active chronic lesions (termed "smoldering") characterised by a core of complete demyelination and a periphery with activated microglial/macrophage elements.
The presence of this 'peripheral rim' can be quantitatively assessed in vivo by QSM (Quantitative Susceptibility Mapping) magnetic resonance sequences with 3T magnetic field study with good reliability compared to the histological correlate.
The association and fusion of structural MRI imaging data (related to both areas of demyelination and iron deposits) with PET data (related to amyloid deposits) may better allow to identify, within a cohort of patients with chronic demyelinating lesions, smoldering type lesions where demyelination process is still in progress and which therefore, in addition to indicating a predictive factor for the failure of the remyelination process, correlate with a longer duration of the disease and a more progressive course.
Dosimetry PET/CT examination with 18F-Florbetaben is justified in view of the risk/benefit ratio for the patient. Following administration of the radiopharmaceutical, the patient will inevitably receive a certain dose of radiation. The activity to be administered was set at 300 MBq, which is below the upper limit of 360 MBq, in order to obtain a PET examination of good diagnostic accuracy with a reasonable radiation dose.
The demyelination plaques have on their outer edge a thin wall of iron-containing microglial cells that can be detected by high-resolution magnetic susceptibility MRI sequences and techniques. Such plaques, known by neuropathologists as 'smoldering' plaques, are characterised by a concentrically widening periphery causing myelin and neuronal damage while in the centre of the lesion the process of myelin loss becomes complete. Smoldering plaques, more frequent in progressive forms of the disease, are peculiar of MS compared to other demyelinating diseases and are associated with a negative prognostic significance.
Positron Emission Tomography (PET) is a technique that allows to analyze the in vivo metabolism of certain components of the central nervous system, such as neurons and glia, and, in particular cases, to highlight synaptic function and abnormal protein accumulations. In recent years, PET has been used in MS especially for research purposes: it allows to assess the degree of demyelination and remyelination by using amyloid tracers that bind to the white substance, as well as the degree of microglial activation or synaptic impairment applying particular tracer radio isotopes (TPSO ligands or the glycoprotein 2A of synaptic vesicles). The combination of MRI and PET could provide detailed information not only on the degree and extent of the nervous system impairment, but also on the most affected cell populations, on the metabolic activity of the affected encephalic areas and on the degree of success of the damage repair attempts.
The aim of this research project is to study, applying MRI and PET techniques, a population of progressive MS patients (PMS) with a relatively significant impairment and a population of patients with a relapsing-remitting form of the disease (RRMS) with a less significant neurological impairment. The purpose is to study chronically active or 'smoldering' plaques, with magnetic susceptibility MRI techniques and PET techniques with amyloid tracers, chronically inactive plaques and more recent T2/Flair positive plaques, with or without contrast enhancement, in order to verify and quantify their presence and to correlate their number, morphology and location with the degree of disability, the clinical course, the evolution of the disease and the laboratory data, evaluating in each case the extent of demyelination and remyelination process and the degree of activation of innate immunity. The data obtained will be processed and evaluated to identify MRI and PET differences in the various disease courses and to obtain information on the different desease development paths in patients.
Study design Enrolled patients will undergo a brain MRI, a brain PET scan with amyloid tracer and functional assessment scales at the time of recruitment.
All patients will undergo clinical evaluation and various tests:
* EDSS and MS Functional Composite Scale
* Mini-BESTest
* TUG test, MSWS-12, Berg Balance Scale (BBS)
* The nine hole peg test (9-HPT) for right and left upper limb.
* Cognitive functions assessed by Brief International Cognitive Assessment for MS (BICAMS) and MMSE
Laboratory analysis of serum markers will be performed. Specifically, neuronal and glial cytoskeletal proteins (e.g. Nf-L, pN-FH, GFAP) as brain damage indices (axonal and cellular damage), will be considered and quantified.
The levels of specific neurotrophic factors (e.g. BDNF, GDNF) and cytokines (e.g. TNFα, IL-6, IL-1β, interferon) will be determined; there is evidence of their involvement in synaptic plasticity, cognitive and motor functions, and in the neuroinflammatory processes typical of MS.
MRI protocol Examinations will be performed on a 3T MRI scanner using a 32-channel head coil with sequences optimised and harmonised by the IRCCS Neuroscience Network.
The sequences that will be acquired will be:
1. T1-weighted sagittal volumetric image (MP-RAGE, 1 mm resolution) to study the morphology and encephalon volumetry
2. T2-FLAIR weighted sagittal volumetric image (1 mm resolution) for lesion localisation and contouring
3. a sequence of diffusion-weighted images (EPI, 2.5 mm resolution, b=1000 and 2000 s/mm2, 30 directions per shell) for the study of tissue microstructure and for the identification of pathology-relevant white matter bundles by tractography
4. a 3D multi-echo gradient echo sequence for quantitative susceptibility mapping (1 mm resolution, 8 echoes) for the study of local susceptibility
5. an fMRI resting-state sequence (EPI, 3 mm resolution, 200 volumes with a temporal resolution of 2.4 s) for the study of functional resting state networks.
PET protocol
The PET/CT study will be performed using a dual time acquisition protocol:
\- Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.
A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.
Early acquisition will last 30 minutes.
\- Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake.
All PET reconstructions will have the following characteristics:
* 256 x 256 matrix, FOV 30 cm
* 3D-OSEM reconstruction algorithm with TOF and PSF and with standard corrections for decay, attenuation, scatter, dead time
* 8 iterations, 32 subsets, Gaussian filter with FWHM of 5 mm. Raw data will be available for possible different iterations, decided a posteriori, to improve image quality.
Patients do not need to be fasting or suspending current therapies.
MRI and PET evaluations MRI
1. Automated encephalic morpho-volumetric study (Freesurfer), by acquisition of conventional sequences (T2w, FLAIR 3D, T1w-3D), harmonised according to RIN protocol:
1. cortical thickness;
2. global brain atrophy;
3. lesions burden;
4. Normal-Appearing White Matter (NAWM).
2. Detection and study of chronic "smoldering" lesions using the QSM technique, which allows both qualitative and quantitative assessments of the extent of intralesional iron accumulation:
1. Qualitative assessment:
* Identification of Rim+ lesions, defined as "non-enhancing lesions with hyperintense perilesional rim", with iso-ipointense core;
* Calculation of the global volume of Rim+ lesions (in mm3), with subsequent separate measurement of core and Rim.
2. Quantitative assessment
* calculation of the global susceptibility of the Rim+ lesions (expressed in ppb: parts per billion), compared to the CSF reference value;
* calculation of susceptibility of Rim and core, separately.
3. Active lesions evaluation by assessing:
1. Number of lesions showing contrastographic enhancement (qualitative assessment);
2. Type of enhancement (nodular or shell-enhancement). The various parameters will be evaluated by three operators (radiologists with expertise in neuroradiology), with consensus agreement and a double check at 4 months after the first evaluation.
PET A slightly abbreviated protocol will be used with a 30-minute dynamic acquisition immediately after the injection of 18F-Florbetaben followed by a 20-minute delayed acquisition (this performed between 90 and 110 minutes after injection). The tracer binds to NAWM and in minor extent to the actively demyelinating plaques, which will be quantified. In addition, a semi-quantitative objective methodology will be used to obtain data on the degree of demyelination of the different cases examined by comparison of the data of the region of interest under investigation with NAWM uptake and a reference area uptake.
In particular, the semi-quantification foreseen is a SUVr where the uptake ROIs are the lesions pre-segmented by the neuroradiologist on MRI (FLAIR and T1 sequences), while for the reference ROIs several possibilities will be evaluated: the contralateral uptake ROIs (i.e. in the white matter if apparently normal on MRI), the white matter hot-spots in the late acquisition, the white matter average with the exclusion of the uptake ROIs. The dynamic uptake profile from the early acquisition will also be assessed, using different temporal reconstructions.
This semi-quantitative evaluation will be carried out in collaboration with colleagues from Nuclear Medicine and the National Institute of Nuclear Physics in Genoa, who have extensive experience in the field and have recently published semi-quantitative methods for the evaluation of PET investigation in Alzheimer's disease.
Sample size
This is an exploratory study of correlation between clinical, laboratory, MRI and PET findings. Considerations on sample size are omitted in the current study and may be included and perfectionated in future confirmatory studies.
Expected results The main objective of the study will be to verify the presence of correlations between PET and MRI images indicative of chronic inflammatory activity (smoldering plaques), of apparent absence of inflammatory activity (silent plaques without microglial Rim) or indicative of more recent inflammatory activity, in contrast-enhancing areas or in T2/Flair positive areas of not distant onset.
PET data will be correlated with conventional MRI parameters, and with clinical and laboratory data. The finding of significant correlations would support the role of PET as a useful tool for evaluating demyelination and remyelination activity, which may be characteristic of a certain disease phase or even possibly of specific types of individual patients.
Particular attention will be paid to study chronic lesions considering the promising results reported in recent studies showing the possibility to distinguish silent lesions from active chronic lesions (termed "smoldering") characterised by a core of complete demyelination and a periphery with activated microglial/macrophage elements.
The presence of this 'peripheral rim' can be quantitatively assessed in vivo by QSM (Quantitative Susceptibility Mapping) magnetic resonance sequences with 3T magnetic field study with good reliability compared to the histological correlate.
The association and fusion of structural MRI imaging data (related to both areas of demyelination and iron deposits) with PET data (related to amyloid deposits) may better allow to identify, within a cohort of patients with chronic demyelinating lesions, smoldering type lesions where demyelination process is still in progress and which therefore, in addition to indicating a predictive factor for the failure of the remyelination process, correlate with a longer duration of the disease and a more progressive course.
Dosimetry PET/CT examination with 18F-Florbetaben is justified in view of the risk/benefit ratio for the patient. Following administration of the radiopharmaceutical, the patient will inevitably receive a certain dose of radiation. The activity to be administered was set at 300 MBq, which is below the upper limit of 360 MBq, in order to obtain a PET examination of good diagnostic accuracy with a reasonable radiation dose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Multiple Sclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-Florbetaben PET/CT scan
All the partecipants will undergo PET/CT scan evaluation after 18F-florbetaben administration
Group Type
EXPERIMENTAL
18F-florbetaben PET/CT
Intervention Type
DIAGNOSTIC_TEST
The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.
Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.
A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.
Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-florbetaben PET/CT
The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.
Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.
A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.
Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake.
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* progressive stage of multiple sclerosis (both secondary and primary, SMP)
* patients in relapsing-remitting multiple sclerosis (RRMS)
* patients in relapsing-remitting multiple sclerosis (RRMS)
Exclusion Criteria
* a disability greater than 7
* patients with a cognitive impairment interfering with full study participation (Minimental score less than 24)
* patients with internal medical problems that in the opinion of the investigator may interfere with full participation and collaboration
* inability to undergo MRI or PET examinations
* ongoing pregnancy and lactation
* patients with a cognitive impairment interfering with full study participation (Minimental score less than 24)
* patients with internal medical problems that in the opinion of the investigator may interfere with full participation and collaboration
* inability to undergo MRI or PET examinations
* ongoing pregnancy and lactation
Minimum Eligible Age
18 Years
Maximum Eligible Age
99 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituti Clinici Scientifici Maugeri SpA
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe Trifirò, MD
Role: PRINCIPAL_INVESTIGATOR
ICS Maugeri Spa SB IRCCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICS Maugeri SpA SB IRCCS
Pavia, PV, Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
References
Explore related publications, articles, or registry entries linked to this study.
Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, Ohayon J, Wu T, Cortese ICM, Reich DS. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol. 2019 Dec 1;76(12):1474-1483. doi: 10.1001/jamaneurol.2019.2399.
Reference Type
BACKGROUND
Maggi P, Sati P, Nair G, Cortese ICM, Jacobson S, Smith BR, Nath A, Ohayon J, van Pesch V, Perrotta G, Pot C, Theaudin M, Martinelli V, Scotti R, Wu T, Du Pasquier R, Calabresi PA, Filippi M, Reich DS, Absinta M. Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Ann Neurol. 2020 Nov;88(5):1034-1042. doi: 10.1002/ana.25877. Epub 2020 Sep 9.
Reference Type
BACKGROUND
Absinta M, Lassmann H, Trapp BD. Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol. 2020 Jun;33(3):277-285. doi: 10.1097/WCO.0000000000000818.
Reference Type
BACKGROUND
Bagnato F, Gauthier SA, Laule C, Moore GRW, Bove R, Cai Z, Cohen-Adad J, Harrison DM, Klawiter EC, Morrow SA, Oz G, Rooney WD, Smith SA, Calabresi PA, Henry RG, Oh J, Ontaneda D, Pelletier D, Reich DS, Shinohara RT, Sicotte NL; NAIMS Cooperative. Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. J Neuroimaging. 2020 May;30(3):251-266. doi: 10.1111/jon.12700.
Reference Type
BACKGROUND
Stankoff B, Poirion E, Tonietto M, Bodini B. Exploring the heterogeneity of MS lesions using positron emission tomography: a reappraisal of their contribution to disability. Brain Pathol. 2018 Sep;28(5):723-734. doi: 10.1111/bpa.12641.
Reference Type
BACKGROUND
Bodini B, Stankoff B. PET is necessary to make the next step forward in understanding MS pathophysiology - Yes. Mult Scler. 2019 Jul;25(8):1086-1087. doi: 10.1177/1352458519828298. Epub 2019 Feb 27. No abstract available.
Reference Type
BACKGROUND
Hogel H, Rissanen E, Vuorimaa A, Airas L. Positron emission tomography imaging in evaluation of MS pathology in vivo. Mult Scler. 2018 Oct;24(11):1399-1412. doi: 10.1177/1352458518791680. Epub 2018 Aug 9.
Reference Type
BACKGROUND
Calvi A, Haider L, Prados F, Tur C, Chard D, Barkhof F. In vivo imaging of chronic active lesions in multiple sclerosis. Mult Scler. 2022 Apr;28(5):683-690. doi: 10.1177/1352458520958589. Epub 2020 Sep 23.
Reference Type
BACKGROUND
Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurol. 2018 Oct 1;75(10):1215-1224. doi: 10.1001/jamaneurol.2018.1836.
Reference Type
BACKGROUND
Chincarini A, Peira E, Morbelli S, Pardini M, Bauckneht M, Arbizu J, Castelo-Branco M, Busing KA, de Mendonca A, Didic M, Dottorini M, Engelborghs S, Ferrarese C, Frisoni GB, Garibotto V, Guedj E, Hausner L, Hugon J, Verhaeghe J, Mecocci P, Musarra M, Queneau M, Riverol M, Santana I, Guerra UP, Nobili F. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). Neuroimage Clin. 2019;23:101846. doi: 10.1016/j.nicl.2019.101846. Epub 2019 May 4.
Reference Type
BACKGROUND
Bodini B, Veronese M, Garcia-Lorenzo D, Battaglini M, Poirion E, Chardain A, Freeman L, Louapre C, Tchikviladze M, Papeix C, Dolle F, Zalc B, Lubetzki C, Bottlaender M, Turkheimer F, Stankoff B. Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis. Ann Neurol. 2016 May;79(5):726-738. doi: 10.1002/ana.24620.
Reference Type
BACKGROUND
Kaunzner UW, Kang Y, Zhang S, Morris E, Yao Y, Pandya S, Hurtado Rua SM, Park C, Gillen KM, Nguyen TD, Wang Y, Pitt D, Gauthier SA. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain. 2019 Jan 1;142(1):133-145. doi: 10.1093/brain/awy296.
Reference Type
BACKGROUND
Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, Schmalbrock P, Pitt D. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One. 2013;8(3):e57573. doi: 10.1371/journal.pone.0057573. Epub 2013 Mar 14.
Reference Type
BACKGROUND
Absinta M, Sati P, Fechner A, Schindler MK, Nair G, Reich DS. Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI. AJNR Am J Neuroradiol. 2018 Jul;39(7):1233-1238. doi: 10.3174/ajnr.A5660. Epub 2018 May 3.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CE 2585
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
PET Study in Multiple Sclerosis
NCT03787446
UNKNOWN
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975
RECRUITING
NA
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
NCT04699747
RECRUITING
PHASE1
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
NCT04144257
UNKNOWN
PHASE1/PHASE2
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
NCT03872583
COMPLETED
NA
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248
RECRUITING
Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)
NCT02301247
COMPLETED
NA
To Study the Pathophysiological Features of Multiple Sclerosis
NCT04242056
UNKNOWN
PHASE1/PHASE2
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
NCT03983252
WITHDRAWN
PHASE1/PHASE2
Entire-body PET Scans for Multiple Sclerosis
NCT04390009
RECRUITING
EARLY_PHASE1
Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters
NCT03108573
COMPLETED
Application of Multiparametric Structural and Functional MRI in Unraveling the Substrates of Cognitive Impairment and Disability in Multiple Sclerosis
NCT06653283
NOT_YET_RECRUITING
Multimodal Imaging of MS Reveals the Smoldering Inflammation
NCT04126772
ACTIVE_NOT_RECRUITING
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
NCT01517282
COMPLETED
PHASE1/PHASE2
Smoldering Inflammation in MS
NCT06591429
RECRUITING
Clinical Disease Activity With Long Term Natalizumab Treatment
NCT02677077
COMPLETED
MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis
NCT05491031
RECRUITING
NA
MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis
NCT03356366
ACTIVE_NOT_RECRUITING
NA
Ultra-high-field Brain MRI in Multiple Sclerosis
NCT05718947
COMPLETED
PET Imaging of Cyclooxygenase in Multiple Sclerosis
NCT05062083
TERMINATED
PHASE2
Cerebrovascular Changes in Multiple Sclerosis Patients
NCT03709290
UNKNOWN
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655
TERMINATED
PHASE2
Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients
NCT01918501
UNKNOWN
NA
Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II
NCT03797937
COMPLETED
NA
Flupirtine as Oral Treatment in Multiple Sclerosis
NCT00623415
TERMINATED
PHASE2